<DOC>
	<DOCNO>NCT02340169</DOCNO>
	<brief_summary>The objective study evaluate potential Topicort® ( desoximetasone ) Topical Spray , 0.25 % suppress hypothalmic pituitary adrenal axis function . The secondary objective evaluate efficacy parameter , pharmacokinetics adverse event profile .</brief_summary>
	<brief_title>Adrenal Suppression Pharmacokinetics Topicort® Spray , 0.25 % Pediatric Patients With Plaque Psoriasis</brief_title>
	<detailed_description>An open label , post marketing safety study assess potential TOPICORT® ( desoximetasone ) Topical Spray , 0.25 % suppress HPA axis function follow twice daily dose 28 day .</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Desoximetasone</mesh_term>
	<criteria>Patients age 7 year old must provide write assent accompany write informed consent patient 's representative Clinical diagnosis stable plaque psoriasis involvement ≥ 10 % body surface area ( exclude face scalp ) Physicians Global Assessment score 3 4 baseline Has dermatological condition may interfere clinical assessment Allergy sensitivity corticosteroid drug hypersensitivity intolerance would compromise patient safety study result History adverse reaction Cortrosyn™ similar test reagent Chronic infectious disease , system organ disorder medical condition would place patient undue risk study participation</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>